Compare AbbVie Inc (ABBV) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Koninklijke Philips NV — how do they compare? AbbVie Inc trades at $249.99 (market cap $438.19B), while Koninklijke Philips NV trades at $27.09 (market cap $26.33B). The key difference: AbbVie Inc is far larger — about 16.6× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.76%). Which is the better fit depends on your goals.
| ABBV | PHG | |
|---|---|---|
Market Cap | $438.19B | $26.33B |
Sector | Health | Health |
52-Week High | $263.58 | $32.91 |
52-Week Low | $197.38 | $25.02 |
Enterprise Value | $502.45B | $32.89B |
Dividend Yield | 2.79% | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
PHG trades at $26.73, up 1.52% today, with a bullish technical signal and recent earnings beats in Q4 2025, Q1 2026, and Q2 2026. The company reported $17.83B revenue and $895M net income for 2025, with a P/E of 20.29 and net margin of 6.31%. Recent news highlights Exor increasing its stake and FDA clearances for new health tech products, supporting positive sentiment.
Outlook is cautiously optimistic with strong profitability and institutional interest, but risks include order intake volatility and debt levels. Analysts show 40.9% buy ratings, indicating potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
